F2G Biotech GmbH

🇦🇹Austria

Country: 🇦🇹Austria

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Active:1

Completed:15

Trial Phases

3 Phases

Phase 1:19

Phase 2:1

Phase 3:1

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (21 trials with phase data)• Click on a phase to view related trials

Phase 1

19 (90.5%)

Phase 2

1 (4.8%)

Phase 3

1 (4.8%)

A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Renal Impairment

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Drug: Olorofim

First Posted Date: 2022-01-20

Last Posted Date: 2023-01-20

Lead Sponsor: F2G Biotech GmbH

Target Recruit Count: 16

Registration Number: NCT05200286

Locations: 🇺🇸
Omega Research, Orlando, Florida, United States

Olorofim Aspergillus Infection Study

Phase 3

Recruiting

Conditions: Invasive Aspergillosis

Interventions: Drug: AmBisome®
Drug: Olorofim

First Posted Date: 2021-11-01

Last Posted Date: 2024-08-06

Lead Sponsor: F2G Biotech GmbH

Target Recruit Count: 225

Registration Number: NCT05101187

Locations: 🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada
🇨🇦
University Health Network, Toronto, Ontario, Canada
🇫🇷
Institut Universitaire du Cancer de Toulouse- IUCT-O, Toulouse, Haute Garonne, France

and more 137 locations

A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Hepatic Impairment

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: Olorofim

First Posted Date: 2021-02-12

Last Posted Date: 2022-03-16

Lead Sponsor: F2G Biotech GmbH

Target Recruit Count: 32

Registration Number: NCT04752540

Locations: 🇺🇸
Orange County Research Centre, Tustin, California, United States
🇺🇸
Orlando Clinical Research Centre, Orlando, Florida, United States